AMGN MEXC RealStocks
Own real AMGN shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 22:58:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Amgen Inc. (AMGN) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $467.05, with a market capitalization of $251.65B and a P/E ratio of 26.96. Over the past 52 weeks, its price has ranged from $312.39 to $483.99. This page covers its latest market performance, valuation, price trends and company information.
$251.65B | |
$471.86 | |
$473.76 | |
$467.05 | |
$468.11 | |
833.89K | |
2.80M | |
26.96 | |
$483.99 | |
$312.39 | |
2.12% | |
12-31 |
Amgen Inc. (AMGN) is trading at $469.38 in after-hours trading as of 2026-11-12 22:54:00, up 0.50% ($2.33) from the regular-session close of $467.05.
After-hours trading shows how investors are pricing AMGN after the regular session closes. The current after-hours price is near the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Amgen Inc. (AMGN) moved from $461.26 to $467.05, representing a gain of 1.26% ($5.79).
The stock traded between $447.04 and $483.99 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 2.88 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 90.1%
AMGN is currently trading at $467.05, placing it 90.1% of the way from its 52-week low of $312.39 to its 52-week high of $483.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 31,500 |
| CEO | Robert A. Bradway |
| Founded | 1980 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Amgen Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Amgen Inc. (AMGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to AMGN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between AMGN shares and USD.
AMGN Shares to USD
1.00 AMGN shares = 467.049 USD
Calculations are estimates based on the latest available price and are for reference only.